Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program

Background SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels. Procedures SCH 727965 was tested against the PPTP in vitro panel using 96 hou...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2012-12, Vol.59 (7), p.1266-1274
Hauptverfasser:	Gorlick, Richard, Kolb, E. Anders, Houghton, Peter J., Morton, Christopher L., Neale, Geoffrey, Keir, Stephen T., Carol, Hernan, Lock, Richard, Phelps, Doris, Kang, Min H., Reynolds, C. Patrick, Maris, John M., Billups, Catherine, Smith, Malcolm A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cell Line, Tumor Child Cyclin-Dependent Kinases - antagonists & inhibitors developmental therapeutics dinaciclib Disease-Free Survival Dose-Response Relationship, Drug Drug Evaluation, Preclinical Female Humans Mice Mice, Inbred C57BL Mice, Nude Mice, SCID Neoplasm Transplantation Neoplasms, Experimental - drug therapy preclinical testing Pyridinium Compounds - pharmacokinetics Pyridinium Compounds - therapeutic use SCH 727965 Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!